Abrégé

An apparatus for measuring a center deviation of a contact lens includes a data augmentation unit configured to augment original contact lens image data photographed during a contact lens manufacturing process, an artificial intelligence learning unit configured to use a dataset augmented by the data augmentation unit as an input to conduct learning through an artificial intelligence learning model, and detect a center point of a colored area and a center point of a frame area of the contact lens through learning, and a measuring unit configured to measure the center deviation using the center point of the colored area and the center point of the frame area detected through the artificial intelligence learning model in the artificial intelligence learning unit. There is an effect of quickly and accurately detecting an off-center defect of a contact lens, thereby reducing a defect rate and increasing production efficiency.

Classes IPC  ?

• G02C 7/04 - Lentilles de contact pour les yeux
• G02C 7/02 - VerresSystèmes de verres

Abrégé

The present invention relates to a deep learning-based SOH estimation system and a method thereof. The present invention relates to a technology capable of learning various patterns and further improving SOH estimation performance by adding area information as well as the voltage positions and heights of peaks and valleys of a DTV curve to DTV-based health indicators (HI) extracted for use when estimating the SOH of a battery on the basis of deep learning.

Classes IPC  ?

• G01R 31/392 - Détermination du vieillissement ou de la dégradation de la batterie, p. ex. état de santé
• G01R 31/396 - Acquisition ou traitement de données pour le test ou la surveillance d’éléments particuliers ou de groupes particuliers d’éléments dans une batterie
• G01R 31/367 - Logiciels à cet effet, p. ex. pour le test des batteries en utilisant une modélisation ou des tables de correspondance
• G01R 31/382 - Dispositions pour la surveillance de variables des batteries ou des accumulateurs, p. ex. état de charge
• G01R 31/36 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p. ex. de la capacité ou de l’état de charge
• G01R 31/374 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p. ex. de la capacité ou de l’état de charge avec des moyens pour corriger la mesure en fonction de la température ou du vieillissement
• G01R 19/12 - Mesure d'un taux de variation
• G01R 19/165 - Indication de ce qu'un courant ou une tension est, soit supérieur ou inférieur à une valeur prédéterminée, soit à l'intérieur ou à l'extérieur d'une plage de valeurs prédéterminée
• G01R 19/30 - Mesure de la valeur maximale ou minimale d'un courant ou d'une tension atteinte dans un intervalle de temps

Abrégé

The present invention relates to a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL S-PAC-PEG S) micelle in which osimertinib, etoposide, and docetaxel are encapsulated, and used thereof. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein osimertinib, which is a target therapeutic agent, and etoposide and docetaxel, which are both anticancer chemotherapeutic drugs, are encapsulated in a Soluplus®polymer to form micelles, whereby anticancer activity can be effectively induced through an improvement in the solubility of the poorly soluble drug in water and a synergistic action between the drugs. The pharmaceutical composition for cancer treatment according to the present invention enables effective solubilization of osimertinib, etoposide, and docetaxel by encapsulating the poorly soluble drugs in micelles formed using the PCL-PVAc-PEG (Soluplus®) polymer, and thus can be advantageously used as an intravenous injection. With the advantage of avoiding first-pass metabolism in the liver, unlike oral dosage forms, intravenous injection can reduce unnecessary loss of drugs and also increase bioavailability compared to oral dosage forms, and thus is an effective administration method capable of expecting a high effect with the same amount of drugs. Therefore, development of such a formulation allows effective administration of osimertinib, etoposide, and docetaxel. In addition, the composition of the present invention can effectively treat non-small cell lung cancer having an EGFR-sensitive mutation while preventing the development of anticancer drug resistance, which can be caused by single drug administration, by using a targeted therapeutic agent and chemotherapy in combination. Furthermore, the composition of the present invention employs a biocompatible polymer as a material of the micelle and thus has an advantage of being safe for the human body. Moreover, by combining osimertinib, etoposide, and docetaxel at a specific molar ratio and encapsulating same in Soluplus® micelles, the composition of the present invention has excellent encapsulation efficiency of three kinds of drugs and has high monodispersibility having a consistent particle size of 50-60 nm. Thus, the composition can maintain consistent product quality and has excellent formulation stability.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61P 35/00 - Agents anticancéreux

Abrégé

3-83-8 alkyl acetate and a second solvent of a non-aromatic cyclic hydrocarbon to each of a dissolution tank and a precipitation tank; (S2) supplying a composite resin to the dissolution tank, heating the dissolution tank to a dissolution temperature, and, while maintaining the dissolution tank at the dissolution temperature, dissolving a polymer included in the composite resin to obtain a polymer solution; (S3) supplying the polymer solution to the precipitation tank in which the mixed solvent is maintained at a precipitation temperature, and precipitating the polymer included in the polymer solution to obtain a solution including a spherical polymer precipitate; and (S4) performing compression filtration on the solution including the spherical polymer precipitate to obtain a polymer precipitate.

Classes IPC  ?

• C08J 11/08 - Récupération ou traitement des résidus des polymères sans réaction chimique utilisant des solvants sélectifs des constituants polymères
• B29B 17/02 - Séparation de matières plastiques des autres matières
• B29B 17/04 - Désintégration des matières plastiques
• B09B 3/32 - Compression ou compactage
• B09B 3/80 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif impliquant une étape d'extraction
• B09B 3/35 - Déchiquetage, écrasement ou découpage
• B29B 17/00 - Récupération de matières plastiques ou d'autres constituants des déchets contenant des matières plastiques

Abrégé

The present invention provides a method for preparing recycled polymers, the method comprising: (S1) a step for supplying cycloalkyl alkyl ether as a solvent to both a dissolution tank and a precipitation tank; (S2) a step for supplying a composite resin to the dissolution tank and then heating to a dissolution temperature, and dissolving a polymer included in the composite resin while maintaining the dissolution tank at the dissolution temperature to obtain a polymer solution; (S3) a step for supplying the polymer solution to the precipitation tank, in which the solvent is maintained at the precipitation temperature, and precipitating the polymer included in the polymer solution to obtain a solution including a polymer precipitate; and (S4) a step for filtering the solution containing the polymer precipitate to obtain the polymer precipitate.

Classes IPC  ?

• C08J 11/08 - Récupération ou traitement des résidus des polymères sans réaction chimique utilisant des solvants sélectifs des constituants polymères
• B29B 17/00 - Récupération de matières plastiques ou d'autres constituants des déchets contenant des matières plastiques

Abrégé

The present invention relates to a method for the prognosis of acute exacerbation in bronchiectasis using an artificial intelligence model. The method processes clinical data such as BSI and/or FACED scores and demographic information as input, handles missing values, and standardizes the data. The standardized data undergo four-fold cross-validation and are analyzed using a multilayer perceptron (MLP) model to acquire outputs through which the acute exacerbation of bronchiectasis can be prognosed. Through the process of analyzing and training with the input data, weights are assigned to individual clinical indicators, thereby improving the accuracy of the output, that is, the prediction results.

Classes IPC  ?

• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G06N 3/0464 - Réseaux convolutifs [CNN, ConvNet]

Abrégé

The present invention relates to a T-shaped joint welding structure for improving welding strength and specifically, to a T-shaped joint welding structure for improving welding strength, the structure comprising: a first to-be-welded body; a second to-be-welded body in which an end of the first to-be-welded body is in vertical contact with one surface of the second to-be-welded body; a first welding bead formed along a contact line of the first to-be-welded body and the second to-be-welded body; and second welding beads having a constant thickness, which are provided on the upper surface of the first welding bead at regular intervals and each have one side surface connected to the first to-be-welded body, the other side surface connected to the second to-be-welded body, and a lower surface in close contact with the upper surface of the first welding bead, thus having the effect of improving the strength of a welding part by stacking the second welding beads on the first welding bead.

Classes IPC  ?

• B23K 9/02 - Soudage de joints continusSupportsPièces rapportées
• B23K 9/025 - Soudage de joints continusSupportsPièces rapportées pour des joints rectilignes
• B23K 31/00 - Procédés relevant de la présente sous-classe, spécialement adaptés à des objets ou des buts particuliers, mais non couverts par un seul des groupes principaux
• B23K 101/18 - Panneaux en tôle

Abrégé

The present invention relates to a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 and use thereof. Specifically, the present invention relates to a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 virus, a composition for detecting an envelope protein of SARS-CoV-2 virus, comprising the DNA aptamer as an active ingredient, a kit for detecting SARS-CoV-2 virus, a chip or microarray for detecting SARS-CoV-2 virus, and a method for detecting an envelope protein of SARS-CoV-2 virus, using the DNA aptamer. Also, the present invention relates to: a composition for diagnosing coronavirus infection-19 and a pharmaceutical composition for preventing or treating coronavirus infection-19, each composition comprising the DNA aptamer of the present invention as an active ingredient; a method for producing a DNA aptamer specifically binding to an envelope protein of SARS-CoV-2 virus; and a method for providing information necessary for diagnosing coronavirus infection-19.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Microspheres for lithium secondary batteries, according to the present invention, may each include: silicon (Si) nanocrystals; an amorphous compound including a transition metal and a chalcogen; and carbon nanotubes (CNTs). A method for preparing the microspheres for lithium secondary batteries, according to the present invention, may include the steps of: preparing a mixture by mixing a transition metal salt, a carbon source, and silicon (Si) nanopowder; producing droplets through ultrasonic spraying of the mixture; performing spray pyrolysis on the droplets; performing a first heat-treatment on the microspheres obtained through the spray pyrolysis; performing a secondary heat treatment for chalcogenization on the microspheres obtained through the first heat treatment; and performing a third heat treatment for oxidation on the microspheres obtained through the second heat treatment. A negative electrode material composition for lithium secondary batteries, according to the present invention, may include the microspheres. A lithium secondary battery, according to the present invention, may include the microspheres.

Classes IPC  ?

• H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
• H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
• H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
• H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
• C01B 33/02 - Silicium
• C01B 19/00 - SéléniumTellureLeurs composés
• H01M 10/052 - Accumulateurs au lithium
• H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif

Abrégé

In a method for determining a false flag of a cyber attack, cyber infringement information is collected from an external server. Artifacts are selected from the collected cyber infringement information according to a preset criterion. Evaluation indicators are classified according to properties of the selected artifacts. A false flag index is calculated based on the classified evaluation indicators.

Classes IPC  ?

• H04L 9/40 - Protocoles réseaux de sécurité

Abrégé

Disclosed are a method for determining a false flag of a cyber attack and an apparatus for performing same. Provided are the method for determining a false flag of a cyber attack, which is performed by a computing apparatus comprising one or more processors and a memory that stores one or more programs executed by the one or more processors, and the apparatus for performing same, according to an embodiment of the present invention, the method comprising the steps of: the computing apparatus collecting cyber infringement information from an external server; the computing apparatus selecting an artifact from among the collected cyber infringement information according to a preset criterion; the computing apparatus classifying as an indicator of evaluation according to an attribute of the selected artifact; and the computing apparatus calculating a false flag index on the basis of the classified indicator of evaluation.

Classes IPC  ?

• G06F 21/56 - Détection ou gestion de programmes malveillants, p. ex. dispositions anti-virus
• G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
• H04L 9/40 - Protocoles réseaux de sécurité

Abrégé

The present invention relates to a use of GRP78, and a similar peptide thereof or a nucleic acid encoding same. The peptide or nucleic acid according to the present invention can increase the expression of a biomarker having reduced expression in senescent cells, and thus is useful for restoring functions, and the like, of muscle tissue of which functions are reduced by aging.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

An anti-chitinase-3-like protein 1 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising CDRs of table 1 and a heavy chain variable region comprising CDRs of table 2. The antibody is capable of specifically binding to chitinase-3-like protein 1 (CHI3L1) and thus can be used for the prevention or treatment of a CHI3L1-associated disease, or for the diagnosis of the disease.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

The present invention relates to a composition for prevention or treatment of atopic dermatitis, comprising a human monoclonal antibody specific to CHI3L1, and specifically, the present invention relates to a pharmaceutical composition for prevention or treatment of atopic dermatitis, a cosmetic composition for prevention or alleviation of atopic dermatitis, and a health functional food for prevention or alleviation of atopic dermatitis, respectively comprising an anti-CHI3L1 antibody as an active ingredient. The monoclonal antibody specific to CHI3L1, according to the present invention, has the effects of reducing epidermal thickness increased by the development of atopic dermatitis, inhibiting mast cell infiltration, reducing the weight of lymph nodes, inhibiting the expression and production of inflammatory cytokines, and inhibiting the expression of p-STAT3 and CHI3L1, and thus may be usefully employed in the production of a medicine, cosmetics, and a health functional food capable of the effective prevention, alleviation, and treatment of atopic dermatitis.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
• A61Q 19/00 - Préparations pour les soins de la peau
• A23L 33/17 - Acides aminés, peptides ou protéines
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a composition for preventing or treating rheumatoid arthritis, comprising a human monoclonal antibody specific to CHI3L1. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, comprising an anti-CHI3L1 antibody as an active ingredient, and a health functional food for preventing or alleviating rheumatoid arthritis.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A23L 33/17 - Acides aminés, peptides ou protéines
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

r,1minr,1min) to be replaced every minute in a microfluidic system. A drug evaluation system according to various embodiments of the present invention comprises: an inlet for liquid injection into the system; an outlet for liquid discharge; a liquid reservoir for liquid storage; a magnetic stirrer arranged in the reservoir; a pump for controlling liquid flow; and a control unit for controlling the speed of the pump, wherein the control unit can perform the operation of the above-described drug evaluation method.

Classes IPC  ?

• G16C 20/70 - Apprentissage automatique, exploration de données ou chimiométrie
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G16C 20/80 - Visualisation de données
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients

Abrégé

Provided are a semiconductor chip, a method of preparing a semiconductor chip, and an apparatus for manufacturing a semiconductor chip. The method includes separating a semiconductor chip from a laminate, the laminate including a substrate, a lift-off layer on the substrate, and a semiconductor layer on the lift-off layer. The method further includes removing the lift-off layer with an etchant by applying a magnetic field while contacting the laminate and the etchant, to thereby prepare a semiconductor chip.

Classes IPC  ?

• H01L 21/78 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun avec une division ultérieure du substrat en plusieurs dispositifs individuels
• H01L 21/306 - Traitement chimique ou électrique, p. ex. gravure électrolytique
• H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitementAppareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
• H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
• H01L 33/22 - Surfaces irrégulières ou rugueuses, p.ex. à l'interface entre les couches épitaxiales

Abrégé

The present invention relates to a cuttable and consumable tape-type or bar-type preparation containing a pharmacologically active ingredient, and, more specifically, to: a tape-type or bar-type preparation enabling precise drug dose control through tape or bar length; and a method for controlling drug dose through length by using the preparation. The tape-type or bar-type preparation of the present invention has cut lines formed at equal intervals in the longitudinal direction, and contains uniform drug doses according to predetermined lengths, thereby enabling accurate dose measurement customized to the age and the weight of an administration subject (children or adults) and enabling easy cutting by the hands and consumption. That is, in the tape-type or bar-type preparation of the present invention, the length of the tape or bar and the drug dose are proportional to each other so that the length required in administering an appropriate dose according to the age and the weight of an administration subject (children or adults) can be easily measured and cut, and thus errors in dose calculation can be minimized and side effects can be reduced. In addition, the tape-type or bar-type preparation of the present invention is a semi-solid formulation and, unlike a liquid formulation, is easy to hold and be consumed without spillage, has excellent storage stability, and is easy to store and carry.

Classes IPC  ?

• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol

Abrégé

The present invention relates to a pollution prevention device having an air bubble barrier, comprising: a plurality of oil pollution control nets provided at intervals on the surface of water so as to prevent the diffusion of floating matter flowing along the water; and an air bubble net, which is positioned in the water between adjacent oil pollution control nets and forms an air barrier. The air bubble net includes: a fixing part that can be secured to the bottom of a river in which water flows; a dividing part, which is provided at the fixing part and can divide the flowing water into two sides; a pipeline, which is connected to the dividing part and enables air to be discharged therethrough; and a connecting part for connecting the dividing part and the pipeline at an interval therebetween. Therefore, the pollution prevention device having an air bubble barrier can prevent sediment on the bottom surface of the river from floating by splitting the water flowing in the river by means of the dividing part. In addition, when bubbles are generated, the rising of sediment, caused by rising flow, can be prevented.

Classes IPC  ?

• E02B 15/08 - Dispositifs pour réduire la zone polluée sans enlever les substances
• B05B 7/00 - Appareillages de pulvérisation pour débiter des liquides ou d'autres matériaux fluides provenant de plusieurs sources, p. ex. un liquide et de l'air, une poudre et un gaz
• B05B 1/20 - Tuyaux ou goulottes perforés, p. ex. rampes de pulvérisationÉléments de sortie pour ces dispositifs
• B05B 1/00 - Buses, têtes de pulvérisation ou autres dispositifs de sortie, avec ou sans dispositifs auxiliaires tels que valves, moyens de chauffage

Abrégé

The present invention relates to a pharmaceutical composition for preventing or treating drug addiction. According to one aspect, the endocannabinoid is effective in treating drug addiction by reducing the desire for drug self-administration, and has the useful effect of contributing to the improvement of national health.

Classes IPC  ?

• A61K 31/232 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone ayant au moins trois doubles liaisons, p. ex. étrétinate
• A61K 31/08 - Éthers ou acétals acycliques, p. ex. paraformaldéhyde
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Abrégé

Provided is a method for estimating a pose of a target object using a 2D LiDAR-based marker in a mobile robot, the method including acquiring first point cloud data including distance and reflection intensity information using a 2D LiDAR sensor of a mobile robot, extracting second point cloud data corresponding to a high-brightness reflective material included in a marker attached to an object from the first point cloud data, clustering the second point cloud data into at least one cluster, identifying a target cluster corresponding to the target object among the at least one cluster, and estimating a pose of the target object based on change in the target cluster.

Classes IPC  ?

• G01S 17/74 - Systèmes utilisant la reradiation d'ondes électromagnétiques autres que les ondes radio, p. ex. pour l'identification ami–ennemi
• G01S 17/931 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour prévenir les collisions de véhicules terrestres

Abrégé

The present invention provides a method for preparing recycled polymers, the method comprising the steps of: preparing a mixed solvent including a first solvent and a second solvent to supply the mixed solvent to a dissolution tank and a precipitation tank, respectively; supplying a composite resin to the dissolution tank and dissolving same to obtain a dissolution mixture; filtering the dissolution mixture to obtain a polymer solution; and supplying the polymer solution to the precipitation tank and recrystallizing same to obtain a precipitation mixture including recycled polymers.

Classes IPC  ?

• C08J 11/08 - Récupération ou traitement des résidus des polymères sans réaction chimique utilisant des solvants sélectifs des constituants polymères
• C08L 23/06 - Polyéthylène
• C08L 23/12 - Polypropylène

Abrégé

The present invention relates to MPO as a biomarker capable of predicting acute exacerbations of bronchiectasis and to a use thereof. It was confirmed that regardless of the severity of bronchiectasis patients, there is a correlation between MPO concentration and the patients' disease state. It was revealed that MPO concentration significantly increases during an acute exacerbation compared to a stable state. By utilizing this finding, the condition of bronchiectasis patients can be predicted and diagnosed, thereby helping to reduce unnecessary antibiotic use.

Classes IPC  ?

• G01N 33/563 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des fragments d'anticorps
• C12Q 1/28 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase une peroxydase

Abrégé

The present invention provides a double-sided alpha-helical stapled peptide comprising hydrophobic and hydrophilic amino acids, which targets an interleukin-4 (IL-4) receptor, and a use thereof. The stapled peptide of the present invention has been confirmed to inhibit the binding of IL-4 to an IL-4 receptor (IL-4R), and accordingly can be useful in the prevention or treatment of IL-4-related diseases, immune-related diseases, or allergic diseases.

Classes IPC  ?

• C07K 14/54 - Interleukines [IL]
• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale

Abrégé

The present invention relates to a construction accident information calculation system and method. More specifically, the present invention comprises: an accident information DB for storing data including a construction accident case; and a processing unit for receiving an input of the data stored in the accident information DB and accident occurrence day site information related to an accident occurrence day site and outputting similar accident information, wherein the processing unit outputs the similar accident information by comparing the data stored in the accident information DB with the input accident occurrence day site information on the basis of a natural language processing model.

Classes IPC  ?

• G06Q 50/08 - Construction
• G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projetsPlanification d’entreprise ou d’organisationModélisation d’entreprise ou d’organisation
• G06F 16/332 - Formulation de requêtes
• G06F 40/30 - Analyse sémantique

Abrégé

A personal server-based metaverse service platform according to the present invention comprises a first personal server and one or more second personal servers capable of communicating with each other, wherein when a service request is received from a specific second personal server among the one or more second personal servers, the first personal server analyzes the received service request to generate a service program suitable for a user of the specific second personal server, and provides the generated service program to the specific second personal server.

Classes IPC  ?

• G06Q 50/10 - Services
• G06F 21/31 - Authentification de l’utilisateur
• G06T 19/00 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie
• G06F 9/44 - Dispositions pour exécuter des programmes spécifiques

Abrégé

A neurovascular unit-on-a-chip for brain tumor analysis is introduced. For this purpose, the invention includes: a main body; a collagen reservoir with a predefined space in the center of the main body to hold collagen; an endosink positioned on one side of the collagen reservoir and a drug supply port positioned opposite the endosink; a pair of culture media sinks, installed respectively at the endosink and the drug supply port; an endochannel connected to the endosink to allow the flow of cerebrovascular endothelial cells toward the collagen reservoir; a drug supply channel connected to the drug supply port to allow drug flow toward the collagen reservoir; a culture channel connected to the culture media sinks to allow the flow of culture media toward the collagen reservoir.

Classes IPC  ?

• G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p. ex. analyse à injection dans un écoulement
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12N 5/0793 - Neurones
• C12N 5/079 - Cellules neurales
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet

Abrégé

Brassica oleraceacapitatecapitate with an increased content of polyphenol and flavonoid by pretreating Brassica oleracea var. capitate seeds. More specifically, the present invention relates to: a method for cultivating Brassica oleracea var. capitate with an increased content of polyphenol and flavonoid, the method comprising a step for hydropriming and then phototreating Brassica oleracea var. capitate seeds; and a food composition comprising Brassica oleracea var. capitate cultivated by the method.

Classes IPC  ?

• A01G 22/15 - Légumes-feuilles, p. ex. laitue ou épinards
• A01C 1/06 - Enrobage ou préparation des semences
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to a recombinant vector for expressing a heterologous protein, and a method for producing a hand-foot-and-mouth virus-like particle structural protein by using same. The recombinant vector for expressing a heterologous protein, according to the present invention, has been identified to enable production of hand-foot-and-mouth disease virus-like particles in a high yield by mass-producing of structural proteins and controlling the expression level of 3CD for P1 precursor cleavage, and enables low-cost production of an antigenic protein that is structurally accurate. Therefore, the recombinant vector for expressing a heterologous protein and hand-foot-and-mouth virus-like particles produced using same, according to the present invention, can be variously used in the field of prevention and treatment of hand-foot-and-mouth disease.

Classes IPC  ?

• C12N 15/86 - Vecteurs viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/135 - Virus de la fièvre aphteuse
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

The present invention relates to a novel Beauveria bassiana 331R strain with insecticidal and bactericidal activity and use thereof and, in particular, to a novel Beauveria bassiana 331R strain (Accession No.: KACC83066BP) having control activity against both plant pests and plant pathogens, a composition for simultaneous control of pests and plant diseases, comprising the Beauveria bassiana 331R strain as an active ingredient, and a simultaneous control method for pests and plant diseases using the Beauveria bassiana 331R strain. The Beauveria bassiana 331R strain according to the present invention is a pest control source that is safe for humans and animals and the environmental ecosystem and can simultaneously control pests harmful to crops and various plant pathogens, and thus can be effectively used as a new biological agent.

Classes IPC  ?

• C12N 1/14 - ChampignonsLeurs milieux de culture
• A01N 63/30 - Champignons microscopiquesSubstances produites par des champignons microscopiques ou obtenues à partir de ceux-ci
• A01P 3/00 - Fongicides
• A01P 7/02 - Acaricides
• A01G 7/06 - Traitement des arbres ou des plantes en cours de croissance, p. ex. pour prévenir la décomposition du bois, pour teinter les fleurs ou le bois, pour prolonger la vie des plantes
• C12R 1/645 - Champignons

Abrégé

The present invention relates to a novel Metarhizium pinghaense 15R strain with insecticidal and bactericidal activity, and a use thereof. Specifically, the present invention relates to a novel Metarhizium pinghaense 15R strain that exhibits control activity against both plant pests and plant pathogens, a composition containing the Metarhizium pinghaense 15R strain as an active ingredient for the control of both harmful insects and plant diseases, and a method for simultaneously controlling harmful insects and plant diseases using the Metarhizium pinghaense 15R strain. The Metarhizium pinghaense 15R strain according to the present invention is a pest control source safe for humans and animals and the ecological environment and can simultaneously control pests harmful to crops and various plant pathogens, thus finding advantageous applications as a new biological agent.

Classes IPC  ?

• C12N 1/14 - ChampignonsLeurs milieux de culture
• A01N 63/30 - Champignons microscopiquesSubstances produites par des champignons microscopiques ou obtenues à partir de ceux-ci
• A01P 7/02 - Acaricides
• A01P 5/00 - Nématicides
• A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
• A01P 3/00 - Fongicides
• C12R 1/645 - Champignons

Abrégé

A method of measuring an internal resistance of a battery cell and a device therefor are provided. A battery management device includes one or more passive balancing circuits provided for each of one or more battery cells, wherein each passive balancing circuit includes a balancing resistor and a switching element for selectively discharging each battery cell through the balancing resistor, and a control unit configured to determine an alternating current internal resistance of a target battery cell that is subject to cell balancing based on a voltage of the target battery cell before and after a target switching element that is the switching element corresponding to the target battery cell is turned on, and determine a direct current internal resistance of the target battery cell based on an amount of change in the voltage of the target battery cell during a time period after a predetermined time elapses from a time point when the target switching element is turned on.

Classes IPC  ?

• G01R 31/389 - Mesure de l’impédance interne, de la conductance interne ou des variables similaires
• G01R 31/388 - Détermination de la capacité ampère-heure ou de l’état de charge faisant intervenir des mesures de tension
• H02J 7/00 - Circuits pour la charge ou la dépolarisation des batteries ou pour alimenter des charges par des batteries

Abrégé

Disclosed is a novel use of MPK38/MELK as a therapeutic agent for obesity or metabolic diseases specific to middle-aged men. Provided are a pharmaceutical composition and health functional food for preventing or treating obesity or a metabolic disease specific to middle-aged men, containing a murine protein serine-threonine kinase 38 (MPK38) protein or a gene encoding the same as an active ingredient. Obesity and metabolic disorders were found to occur in MPK38-knockout middle-aged male mice. As a result of inducing the expression of MPK38 in MPK38-knockout middle-aged male mice, MPK38 was found to have effects of decreasing the size of adipocytes, suppressing the expression of adipogenic genes, reducing glucose and insulin in the blood, enhancing insulin sensitivity, reducing triglycerides and total cholesterol in the blood, promoting ketone formation, and promoting the production of testosterone, a male hormone, in middle-aged male mice. In particular, it was found that the effects of the MPK38 are specific to middle-aged men and that MPK38 is useful as a therapeutic agent and health functional food for treating obesity or metabolic diseases specific to middle-aged men.

Classes IPC  ?

• A61K 38/45 - Transférases (2)
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose

Abrégé

The present invention relates to a microfluidic device capable of confirming sustained anticancer activity of a drug and the enhanced permeability and retention (EPR) effect of a nanoparticle formulation of the drug, and a method for confirming sustained anticancer activity of a drug and the EPR effect of a nanoparticle formulation of the drug using same. As the microfluidic device according to the present invention has a structure in which an upper cap having a fluid inlet, a fluid outlet, and a fluid passage, and a lower body having a chamber capable of accommodating a tumoroid, are separated, the microfluidic device may easily, quickly, and conveniently accommodate, directly in the chamber, tumoroids of a large size (600 μm or more) suitable for research on anticancer drug-based nanoinjection formulations. In addition, the microfluidic device according to the present invention enables continuous cytotoxicity analysis of an anticancer drug by means of a membrane filter made of a hydrophilic material with a specific pore size (100 to 300 nm) formed between the upper cap and the lower body and, at the same time, has the advantage of being capable of confirming the EPR effect of a nanoparticle formulation of the drug.

Classes IPC  ?

• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

A runoff pump station operating system according to one embodiment of the present invention is an operating system for a runoff pump station into which runoff flows from a drainage point and which discharges the runoff to a discharge point. The runoff pump station operating system comprises: a first waterway into which runoff flows from a drainage point; a retarding basin which receives the runoff from the first waterway and stores the runoff; a second waterway which receives the runoff from the retarding basin and discharges the runoff to the discharge point; a pump module which delivers the runoff in the retarding basin to the discharge point and includes a plurality of pumps; a sensing module including a first water level sensor for sensing the water level at the drainage point and a second water level sensor for sensing the water level in the retarding basin; and a processor which receives the sensing results from the sensing module and controls the driving of the pump module, wherein the processor may sequentially drive the plurality of pumps on the basis of the sensing results of the first and second water level sensors.

Classes IPC  ?

• G06Q 50/06 - Fourniture d’énergie ou d’eau
• G06Q 50/10 - Services
• G01F 15/06 - Dispositifs d'indication ou d'enregistrement
• G01F 23/80 - Dispositions pour le traitement des signaux
• E02B 7/20 - Barrages mobilesPortes d'écluse
• E02B 8/04 - Clapets, vannes glissantes ou analoguesVannes immergées
• F04B 49/06 - Commande utilisant l'électricité
• F04B 49/00 - Commande des "machines", pompes ou installations de pompage ou mesures de sécurité les concernant non prévues dans les groupes ou présentant un intérêt autre que celui visé par ces groupes

Abrégé

Provided is a microchip including a chip body having a first surface and a second surface facing the first surface, and an electrode layer on the second surface, wherein a surface roughness of the first surface is smaller than a surface roughness of an upper surface of the electrode layer such that van der Waals force between the first surface and an external contact surface are greater than van der Waals force between the electrode layer and the external contact surface.

Classes IPC  ?

• H01L 25/16 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant de types couverts par plusieurs des sous-classes , , , , ou , p. ex. circuit hybrides
• H01L 33/38 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les électrodes ayant une forme particulière
• H01L 23/00 - Détails de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide

Abrégé

A conducting wire composition for the direct scanning-type production of a flexible circuit according to the present invention has the advantage of being applicable to a direct scanning method in additive manufacturing in that a highly flexible and optimal epoxy cured body can be produced by adjusting the content of an epoxy resin and a curing agent and the viscosity of an epoxy mixture is optimized by selecting a volatile and non-reactive optimal diluent and adjusting the content thereof. In addition, the conducting wire composition for the direct scanning-type production of a flexible circuit has the advantage that the deterioration of electrical properties caused by residues does not occur because the diluent is completely volatilized and disappears, and has the advantage of not only having low resistivity and excellent electrical conductivity properties because a maximum content of silver flakes, which are electrically conductive materials, are homogeneously dispersed in an epoxy polymer, but also showing an insignificant change in electrical conductivity without breaking even when bent at the maximum curvature.

Classes IPC  ?

• H01B 1/22 - Matériau conducteur dispersé dans un matériau organique non conducteur le matériau conducteur comportant des métaux ou des alliages
• H01B 5/14 - Conducteurs ou corps conducteurs non isolés caractérisés par la forme comprenant des couches ou pellicules conductrices sur supports isolants
• H05K 3/12 - Appareils ou procédés pour la fabrication de circuits imprimés dans lesquels le matériau conducteur est appliqué au support isolant de manière à former le parcours conducteur recherché utilisant la technique de l'impression pour appliquer le matériau conducteur

Abrégé

The present invention relates to: a novel 4-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Classes IPC  ?

• C07D 209/44 - Iso-indolesIso-indoles hydrogénés
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

An anti-chitinase-3-like protein 1 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising CDRs of table 1 and a heavy chain variable region comprising CDRs of table 2.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61P 35/00 - Agents anticancéreux
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a real-time pressure deviation detection system for a magnetic fluid vacuum seal. The system comprises: a magnetic fluid vacuum seal which includes a housing accommodating a rotating shaft for transmitting power from an atmospheric side to a vacuum side, a pair of pole pieces surrounding the rotating shaft from an inner space of the housing, a permanent magnet surrounding the rotating shaft from between the pole pieces, and a magnetic fluid confined between the rotating shaft and the pole pieces by the magnetic force of the permanent magnet; a pressure deviation detection sensor which is installed in the housing so as to communicate with the space between the pole pieces and detects changes in pressure on the atmospheric side and the vacuum side; and a control unit which receives the state of the pressure changes detected by the pressure deviation detection sensor. Therefore, the system has the effect of making it possible to quickly take follow-up measures by accurately identifying where pressure deviations have occurred in real time.

Classes IPC  ?

• F16J 15/43 - Joints d'étanchéité entre deux surfaces mobiles l'une par rapport à l'autre par un fluide maintenu en position d'étanchéité par la force magnétique
• G01L 13/02 - Dispositifs ou appareils pour la mesure des différences entre plusieurs valeurs de la pression des fluides en utilisant des organes ou des pistons élastiquement déformables comme éléments sensibles

Abrégé

The present invention relates to: a novel 6-methoxy-2-phenethyl isoindolin-1-one derivative compound having the ability to promote the increase of nerve growth factor, the ability to promote the growth of nerve cells, and antineuritic activity; and a composition for preventing, improving and treating neurological diseases, comprising the same.

Classes IPC  ?

• C07D 209/46 - Iso-indolesIso-indoles hydrogénés avec un atome d'oxygène en position 1
• C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
• A61P 25/16 - Antiparkinsoniens
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Abrégé

Provided is a convolutional neural network structure based on channel-specific convolution for high-speed object recognition of a 3D LiDAR, including: an inside-channel convolutional network for extracting features in channels of a LiDAR data; an outside-channel convolutional network for extracting features between the channels by using outputs for the channels of the inside-channel convolutional network and generating a feature map representing the extracted features between the channels; and a detection network searching location and class of an object by using the feature map generated from the outside-channel convolutional network. According to the invention, since a raw data coming from a LiDAR is directly used in a high-speed object recognition procedure of a 3D LiDAR, there is an effect that data loss does not occur.

Classes IPC  ?

• G01S 17/894 - Imagerie 3D avec mesure simultanée du temps de vol sur une matrice 2D de pixels récepteurs, p. ex. caméras à temps de vol ou lidar flash
• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
• G06V 10/771 - Sélection de caractéristiques, p. ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux

Abrégé

Disclosed are a method of forming a contact structure, a method of fabricating a semiconductor device, a contact structure, and a semiconductor device including the same. A method of forming a contact structure may comprise forming a porous silicon layer on a substrate by using an epitaxy process, forming a dielectric layer on the porous silicon layer, forming a metal layer on the dielectric layer, forming a silicide member having a three-dimensional structure in the porous silicon layer by diffusing metal atoms of the metal layer into the porous silicon layer through the dielectric layer and reacting the diffused metal atoms with the porous silicon layer in a heat treatment process, removing the metal layer and the dielectric layer, and forming a conductive layer in contact with the silicide member.

Classes IPC  ?

• H10D 64/62 - Électrodes couplées de manière ohmique à un semi-conducteur
• H01L 21/285 - Dépôt de matériaux conducteurs ou isolants pour les électrodes à partir d'un gaz ou d'une vapeur, p. ex. condensation
• H01L 21/768 - Fixation d'interconnexions servant à conduire le courant entre des composants distincts à l'intérieur du dispositif
• H10D 62/83 - Corps semi-conducteurs, ou régions de ceux-ci, de dispositifs ayant des barrières de potentiel caractérisés par les matériaux étant des matériaux du groupe IV, p. ex. Si dopé B ou Ge non dopé
• H10D 64/23 - Électrodes transportant le courant à redresser, à amplifier, à faire osciller ou à commuter, p. ex. sources, drains, anodes ou cathodes

Abrégé

The present invention relates to a PRDX1 mutant for preventing or treating bone diseases. Particularly, the present invention relates to a pharmaceutical composition and health functional food for preventing or treating bond disease, comprising, as an effective ingredient: a peroxiredoxin 1 (PRDX1) mutant protein represented by the amino acid sequence of SEQ ID NO: 3; a PRDX1 mutant gene encoding the PRDX1 mutant protein; or the PRDX1 mutant protein or the PRDX1 mutant gene encoding the protein. The PRDX1 mutant protein according to the present invention has excellent inhibitory ability in differentiation and formation of osteoclasts, and thus can be useful as a medicine and health functional food that can prevent, ameliorate, or treat various bone diseases caused by over-differentiation of osteoclasts.

Classes IPC  ?

• C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
• A23L 33/17 - Acides aminés, peptides ou protéines

Abrégé

Provided is a chimeric antigen receptor (CAR) specifically binding to CD138, an immune cell expressing same, and a pharmaceutical composition for the treatment or prevention of cancer including same as an active ingredient. It was confirmed that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the presently claimed subject matter efficiently exhibits strong cytotoxic ability against CD138-expressing (positive) cancer cells. Accordingly, it is expected that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the presently claimed subject matter can be utilized for the treatment of CD138-expressing (benign) cancer diseases.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
• C07K 14/735 - Récepteurs Fc
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire

Abrégé

Provided are a composition for regulating stem cell function comprising the genus Lactobacillus bacteria-derived extracellular vesicles as an active ingredient, and a method for regulating a stem cell function using the same, wherein the genus Lactobacillus bacterial-derived extracellular vesicles have the effect of greatly improving the proliferation of stem cells, and the extracellular vesicles are naturally secreted from a symbiotic the genus Lactobacillus strain in human tonsillar tissue and are human-friendly and natural substances, and thus can be used in various research fields by promoting the proliferation of aged stem cells with minimal toxicity and side effects.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux

Abrégé

The present invention relates to a personalized item recommendation system comprising: a user terminal unit for providing user-related information; and an agent unit for selecting, as recommendation items, some of items provided by an item provider on the basis of a plurality of pieces of item-related information provided by the item provider and the user-related information provided by the user terminal unit, and transmitting the recommended item-related information to the user terminal unit. Accordingly, it is possible to accurately recommend an item suitable for the tendency of a user.

Classes IPC  ?

• G06Q 30/06 - Transactions d’achat, de vente ou de crédit-bail
• G06Q 30/02 - MarketingEstimation ou détermination des prixCollecte de fonds
• H04W 12/06 - Authentification
• H04W 4/02 - Services utilisant des informations de localisation

Abrégé

The present invention relates to a personalized item suggestion system, the system comprising: a user terminal unit; a prior information collection unit which collects user-related information from the user terminal unit; and an agent unit which, on the basis of the user-related information provided by the prior information collection unit and item-related information provided by a plurality of item providers, selects a part of items provided by the item providers as a suggestion item and transmits information related to the suggestion item to the user terminal unit. The personalized item suggestion system of the present invention can accurately suggest an item suitable for a user's tendency.

Classes IPC  ?

• G06Q 30/06 - Transactions d’achat, de vente ou de crédit-bail
• G06Q 30/02 - MarketingEstimation ou détermination des prixCollecte de fonds
• H04W 12/06 - Authentification

Abrégé

Microspheres of the present invention may comprise: hollow carbon; and a transition metal oxide disposed on the surface of the hollow carbon. A lithium ion battery anode of the present invention may comprise the microspheres. A method for manufacturing microspheres of the present invention may comprise the steps of: mixing a metal salt, a carbon precursor, and an ammonium ion precursor to obtain a spray solution; and subjecting the spray solution to one-pot spray pyrolysis.

Classes IPC  ?

• C01B 32/05 - Préparation ou purification du carbone non couvertes par les groupes , , ,
• C04B 38/00 - Mortiers, béton, pierre artificielle ou articles de céramiques poreuxLeur préparation
• H01M 4/587 - Matériau carboné, p. ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers

Abrégé

A convolutional neural network (CNN) acceleration device having a hierarchical structure composed of a three-dimensional matrix comprises: controllers which are an upper layer of the three-dimensional matrix and disposed in a two-dimensional matrix; convolutional arrays which are a lower layer of the three-dimensional matrix and disposed in the two-dimensional matrix, and which perform convolutional operations for pixel data of input data and filter weights; convolutional memories in which the convolutional operation results of the convolutional arrays are stored for each row of the two-dimensional matrix; and integrated convolutional post-processing devices which are individually connected to the convolutional memories, and which sequentially read memory values stored in the convolutional memories, and apply pooling, batch-normalization, and an activation function to the read memory values, wherein each of the convolutional arrays includes K×K PEs disposed in a K×K matrix, has K diagonal cyclic connections composed of K PEs, and independently performs convolutional operations at each of the K diagonal cyclic connections, where K is an integer of 1 or greater.

Classes IPC  ?

• G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
• G06N 3/04 - Architecture, p. ex. topologie d'interconnexion
• G06F 17/15 - Calcul de fonction de corrélation
• G06F 12/02 - Adressage ou affectationRéadressage
• G06F 3/06 - Entrée numérique à partir de, ou sortie numérique vers des supports d'enregistrement

Abrégé

The present invention relates to a super metaverse operating system and, particularly, to a super metaverse operating system for operating a super metaverse including one or more sub metaverses. The super metaverse operating system according to the present invention enables integrated management of various metaverses.

Classes IPC  ?

• G06Q 50/10 - Services
• G06T 19/00 - Transformation de modèles ou d'images tridimensionnels [3D] pour infographie

Abrégé

Disclosed in the present invention are a vehicle overtaking control method and a vehicle overtaking control device using same, wherein the vehicle overtaking control method, executed by a vehicle overtaking control device, comprises the steps of: collecting vehicle information of a plurality of vehicles located in a vehicle driving management area defined as a communication coverage of a roadside base station; storing the collected vehicle information; setting occupied virtual areas on a road on which each vehicle is driving, on the basis of the stored vehicle information; and setting an overtaking virtual path for a second vehicle that is a following vehicle of the a vehicle and the second vehicle of which the occupied virtual areas overlap each other, wherein the step of setting the overtaking virtual path sets an overtaking virtual path along which the second vehicle moves in front of the first vehicle after moving from a driving lane to an overtaking lane in such a manner that a first occupied virtual area of the first vehicle and a second occupied virtual area of the second vehicle do not overlap each other.

Classes IPC  ?

• G08G 1/16 - Systèmes anticollision
• G08G 1/00 - Systèmes de commande du trafic pour véhicules routiers

Abrégé

Disclosed are a traveling hybrid control method and a traveling hybrid control apparatus using same, the traveling hybrid control method comprising the steps of: a traveling hybrid control apparatus collecting vehicle information of a plurality of vehicles located within management areas defined as a communication range of road side units (RSUs); identifying, on the basis of the collected vehicle information, whether or not there is a vehicle to be moved from a first RSU to a second RSU from among the RSUs; if there is a first vehicle to be moved from the first RSU to the second RSU, detecting the risk of a rear-end collision between the first vehicle and a second vehicle belonging to the second RSU; and if there is the risk of a rear-end collision, adjusting the movement speed of the first vehicle.

Classes IPC  ?

• G08G 1/16 - Systèmes anticollision
• G08G 1/01 - Détection du mouvement du trafic pour le comptage ou la commande
• B60W 30/08 - Anticipation ou prévention de collision probable ou imminente
• B60W 40/105 - Vitesse

Abrégé

The present disclosure in some embodiments provides a coil alignment control method and a coil alignment control apparatus for the wireless charging of a mobile object, which perform a parallel alignment for aligning a power reception-side surface of a power reception coil of the mobile object to be parallel to a power transmission-side surface of a power transmission coil on a wireless-charging power transmission coil panel, perform a center alignment for the power reception coil and the power transmission coil to have central winding areas that are in alignment, and perform a proximity alignment for aligning the power reception coil to be in proximity to the power transmission coil by a preset proximity distance, thereby maximizing the wireless power transfer efficiency.

Classes IPC  ?

• H02J 50/90 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique mettant en œuvre la détection ou l'optimisation de la position, p. ex. de l'alignement
• H02J 50/10 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif
• H02J 50/40 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant plusieurs dispositifs de transmission ou de réception

Abrégé

Provided is an artificial light source setting method and an artificial light source setting system for controlling secondary metabolites of plant and provide an artificial light source setting method and an artificial light source setting system for controlling secondary metabolites of plant, which predict content of the secondary metabolites of plant by measuring a light interception amount by using a cultivation environment of plant, a three-dimensional structure model of plant, and optical simulation and set an artificial light source according thereto.

Classes IPC  ?

• A01G 7/04 - Traitement électrique ou magnétique des végétaux pour favoriser leur croissance
• H05B 47/105 - Commande de la source lumineuse en réponse à des paramètres détectés

Abrégé

According to at least one embodiment, the present disclosure provides an apparatus for single-stage three-dimensional (3D) multi-object detection by using a LiDAR sensor to detect 3D multiple objects, comprising: a data input module configured to receive raw point cloud data from the LiDAR sensor; a BEV image generating module configured to generate bird's eye view (BEV) images from the raw point cloud data; a learning module configured to perform a deep learning algorithm-based learning task to extract a fine-grained feature image from the BEV images; and a localization module configured to perform a regression operation and a localization operation to find 3D candidate boxes and classes corresponding to the 3D candidate boxes for detecting 3D objects from the fine-grained feature image.

Classes IPC  ?

• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
• G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
• G06N 3/08 - Méthodes d'apprentissage
• G06V 10/766 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la régression, p. ex. en projetant les caractéristiques sur des hyperplans
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 20/64 - Objets tridimensionnels

Abrégé

The present invention relates to recombinant E. coli for producing nicotinamide mononucleotide (NMN), and a method for producing nicotinamide mononucleotide by using same, and is technically characterized by: E. coli in which phosphoribosyl transferase (NAMPT), phosphoribosyl pyrophosphate synthase 1 (PRPS1) and phosphoribosyl pyrophosphate synthase 2 (PRPS2) are recombined; and a production method for increasing the production of nicotinamide mononucleotide by using a high cell density fed-batch culture of the E. coli.

Classes IPC  ?

• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 9/10 - Transférases (2.)
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12P 19/30 - Nucléotides

Abrégé

Disclosed is a composition for preventing or treating chronic obstructive pulmonary disease containing regorafenib as an active ingredient, and particularly a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease containing regorafenib or a pharmaceutically acceptable salt thereof as an active ingredient, in which regorafenib is capable of effectively inhibiting increased immune response, which is a symptom of chronic obstructive pulmonary disease, and of improving and restoring changed lung structure and damaged lung function, and can be effectively used for the manufacture of a medicament for the prevention, amelioration, or treatment of chronic obstructive pulmonary disease, such as emphysema, chronic bronchitis, asthma, or pneumonia.

Classes IPC  ?

• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
• A61P 35/00 - Agents anticancéreux

Abrégé

Psidiuma guajavaPsidiuma guajava leaf extract and a fraction thereof, or sesquiterpenoid-based and porphyrin-based compounds isolated therefrom, as an active ingredient. Through synergistic antiviral activity obtained by increasing the amount of an active ingredient derived from a Psidiuma guajava leaf extract and combining the isolated active compounds, the composition can be effectively used in, in particular, the treatment and prevention of novel coronavirus infection.

Classes IPC  ?

• A61K 36/61 - Myrtaceae (famille du myrte), p. ex. cajeputier ou eucalyptus
• A61K 31/015 - Hydrocarbures carbocycliques
• A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
• A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
• A23K 20/105 - Composés aliphatiques ou alicycliques
• A23K 20/121 - Composés hétérocycliques contenant de l’oxygène ou du soufre comme hétéroatome

Abrégé

The present invention relates to a method for inhibiting M2 polarization of macrophages, comprising a humanized monoclonal antibody specific to Chi3L1, and a composition therefor. In addition, the present invention relates to: a composition for preventing or treating cancer or inhibiting cancer metastasis comprising, as an active ingredient, a composition for inhibiting M2 polarization of macrophages; a composition for diagnosing cancer; and a kit therefor, and relates to: a method for screening for candidate substances preventing or treating cancer or inhibiting cancer metastasis; and a composition and a kit therefor. A composition for inhibiting M2 polarization of macrophages, of the present invention, effectively inhibits M2 polarization of macrophages and STAT6 phosphorylation and has the excellent effect of inhibiting tumor growth and metastasis, and thus can be variously used as compositions for preventing and treating cancer and inhibiting cancer metastasis. In addition, a screening method and a composition or kit therefor, of the present invention, are used, and thus therapeutic candidate substances capable of effectively preventing and treating cancer and inhibiting cancer growth and metastasis can be easily and significantly selected.

Classes IPC  ?

• C12N 5/0786 - MonocytesMacrophages
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61P 35/00 - Agents anticancéreux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to use of PAK4 and CRTC1 or the treatment or diagnosis of a degenerative brain disease. Specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising PAK4 (p21-activated kinase 4) or a PAK4 activator as an effective ingredient. In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising a CRTC1 expression enhancer or activator as an effective ingredient, a diagnostic kit for a degenerative brain disease comprising an agent for detecting CRTC1, and a method for screening a substance for the prevention or treatment of a degenerative brain disease, comprising (a) applying a candidate drug to brain tissue or brain cells containing CRTC1 gene or CRTC1 protein; (b) measuring the degree of phosphorylation in CRTC1; and (c) determining the candidate drug as a substance for the prevention or treatment of a degenerative brain disease when the measurement in step (b) indicates that the phosphorylation in CRTC1 is increased.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention relates to an exosome-rich culture medium of immortalized stem cells and a functional composition comprising botulinum toxin. Specifically, the functional composition according to the present invention inhibits the decomposition of collagen and elastin and at the same time promotes the synthesis thereof, improves wrinkles, and promotes cell regeneration, and thus can be usefully used as a functional material for wrinkle improvement, skin regeneration, skin elasticity improvement, skin aging inhibition, or wrinkle prevention, or for wound treatment.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
• C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
• A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
• A61Q 19/00 - Préparations pour les soins de la peau
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61K 35/50 - PlacentaCellules souches placentairesLiquide amniotiqueAmniosCellules souches amniotiques
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A23L 33/17 - Acides aminés, peptides ou protéines

Abrégé

A rheometer according to an embodiment includes a substrate on which an object to be measured is placed, a vibration unit configured to provide a vibration to the substrate, a plurality of probe units each including a quartz tuning fork and a contact member fixed to the quartz tuning fork, the contact member being able to contact the object, the plurality of probe units having different types of the contact members. Any one of the plurality of probe units is selected and contacts the object, and a controller configured to calculate a viscoelastic force of the object based on a vibration of the vibration unit and a vibration transmitted to the quartz tuning fork through the object from the vibration of the vibration unit.

Classes IPC  ?

• G01N 11/16 - Recherche des propriétés d'écoulement des matériaux, p. ex. la viscosité, la plasticitéAnalyse des matériaux en déterminant les propriétés d'écoulement en déplaçant un corps à l'intérieur du matériau en mesurant l'effet d'amortissement sur un corps oscillant
• G01N 21/65 - Diffusion de Raman

Abrégé

The present invention relates to a method for producing a two-dimensional nickel silicate molecular sieve catalyst for dry reforming of methane, wherein a catalyst containing a two-dimensional wide external surface area and nickel bonded to the surface area and having structural stability and activity is produced through hydrothermal treatment in one step.

Classes IPC  ?

• B01J 37/10 - Traitement thermique en présence d'eau, p. ex. de vapeur d'eau
• B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
• B01J 29/76 - Métaux du groupe du fer ou cuivre
• C01B 3/40 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants avec des catalyseurs caractérisée par le catalyseur

Abrégé

The present invention relates to a biomarker composition for predicting the therapeutic effect of mesenchymal stem cells on systemic lupus erythematosus.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

An atomic force microscope includes a sample stage on which a sample is placed, a cantilever including a probe tip, a laser radiating a laser beam to the cantilever, a photodetector receiving a laser beam reflected from the cantilever, a first camera photographing the sample and the cantilever, a second camera photographing the cantilever and the spot of the laser beam, and a processor electrically connected to the first and second cameras and the photodetector to process data acquired by the first and second cameras and the photodetector. An operation method of the atomic force microscope includes detecting the positions of the cantilever and the sample using the first camera, adjusting the position of the sample, detecting the positions of the laser and the cantilever using the second camera, aligning the laser, detecting the position of the laser beam using the photodetector, and aligning the position of the photodetector.

Classes IPC  ?

• G01Q 20/02 - Contrôle du mouvement ou de la position de la sonde par des moyens optiques
• G01Q 10/04 - Balayage ou positionnement fin
• G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras

Abrégé

Disclosed is a method for manufacturing an electrode for alkaline water electrolysis, the method including: dissolving a metal salt in a solvent, followed by synthesis, to prepare a wet powder; performing an oxidative heat treatment on the wet powder; and performing a reductive heat treatment on the oxidatively heat treated powder.

Classes IPC  ?

• C25B 11/031 - Électrodes poreuses
• C25B 11/089 - Alliages
• C25B 11/075 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’un seul élément catalytique ou composé catalytique
• C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau

Abrégé

Provided are a chimeric cytokine receptor capable of converting immunosuppressive signals to immunostimulatory signals, immune cells expressing same, and a method for treatment of cancer using the same, wherein the immune cells expressing the chimeric cytokine receptor convert immunosuppressive signals to immunostimulatory signals in a tumor microenvironment where immunosuppressive cytokines exist, thereby effectuating more potent cytotoxicity against cancer, and therefore the immune cells expressing the chimeric cytokine receptor are useful as a cell therapy product for treatment of cancer.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a biomarker composition for predicting the therapeutic effect of mesenchymal stem cells on renal fibrosis.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux

Abrégé

ChlorellaChlorella sp. extract and a pheophytinized fraction or a porphyrin- or carotenone-based compound isolated therefrom as an active ingredient for prevention or treatment of coronavirus disease-19. The composition has an increased content of the porphyrin-based compounds pheophytin A (compound 1) and phenophytin B (compound 2), which are active compounds, through a chemical method and further contains a carotenone-based compound, thereby finding advantageous applications particularly in the treatment and prevention of coronavirus disease-19 in humans through the synergistic antiviral activity thereof.

Classes IPC  ?

• A61K 36/05 - Chlorophycota ou chlorophyta (algues vertes), p. ex. Chlorella
• A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
• A61K 31/12 - Cétones
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/02 - Antiseptiques locaux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A01N 65/03 - Algues
• A01N 43/90 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant plusieurs hétérocycles déterminants condensés entre eux ou avec un système carbocyclique commun
• A01N 35/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde contenant des groupes aldéhyde ou cétone, ou leurs thio-analogues, liés directement à un système cyclique aromatique, p. ex. acétophénoneLeurs dérivés, p. ex. acétals

Abrégé

Psidiuma guajavaPsidiuma guajava extract, a pheophytin fraction thereof, or a meroterpenoid-based compound isolated therefrom. By increasing, through a chemical method, the content of a porphyrin-related compound, which is an active compound, while containing the meroterpenoid-based compound, the composition may be advantageously used in the treatment and prevention of novel coronavirus infection through synergistic interactions of antiviral activity.

Classes IPC  ?

• A61K 36/61 - Myrtaceae (famille du myrte), p. ex. cajeputier ou eucalyptus
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/02 - Antiseptiques locaux
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
• A23K 20/121 - Composés hétérocycliques contenant de l’oxygène ou du soufre comme hétéroatome
• A01N 65/28 - Myrtaceae [famille du myrte], p. ex. cajeputier ou clou de girofle

Abrégé

The present invention relates to an in vitro analysis method for the risk of virus infection on the basis of a pharyngeal airway tissue-derived cell and, specifically, the present invention relates to: a method, for analyzing whether or not there is virus infection on the basis of a pharyngeal airway tissue-derived cell, comprising a step of using a primary cell isolated from a human pharyngeal airway tissue discarded after a surgery; and a method for screening an antiviral agent on the basis of a pharyngeal tissue-derived cell using the primary cell. In the method for analyzing whether or not there is virus infection using a primary cell isolated from a human pharyngeal airway tissue, a human body-derived primary cell is used in place of an immortalized cell line used in an existing virus infection study. Therefore, the method has the advantages of obtaining more accurate results and economic advantages, reducing unnecessary animal experiments, and efficiently reducing time and cost required for discovery and effectiveness assessment of an antiviral agent. Therefore, the method for analyzing whether or not there is virus infection and screening an antiviral agent using a primary cell isolated from a human pharyngeal airway tissue can be utilized as a platform for verifying effectiveness and safety in developing a therapeutic agent against virus infection diseases having increased attack rates worldwide.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie

Abrégé

The present invention relates to a system and a method for calculating preference through personal information management. The system for calculating preference through personal information management according to the present invention comprises: a terminal unit which collects user-related data, data relating to an object subjected to preference calculation, and public data; a data management unit which calculates a user's preference for the object subjected to preference calculation on the basis of the user-related data, the data relating to the object subjected to preference calculation, and the public data while storing and managing the pieces of data collected by the terminal unit; and a communication unit which transmits data between the terminal unit and the data management unit, and between the terminal unit and the outside. A person's preference, particularly a person's preference related to a vehicle, can be precisely calculated.

Classes IPC  ?

• G01C 21/34 - Recherche d'itinéraireGuidage en matière d'itinéraire
• G01C 21/36 - Dispositions d'entrée/sortie pour des calculateurs embarqués

Abrégé

The present invention relates to immortalized canine stem cells or a use of same, and more specifically, to immortalized canine stem cells obtained by differentiating canine stem cells transduced with a lentivirus vector containing E6 and E7 genes of HPV16, and to a use of the immortalized canine stem cells. By transducing canine stem cells with human papillomavirus E6 and E8 genes, the immortalized canine stem cells of the present invention can obtain canine stem cells having uniform characteristics and efficacy without repeated stem cell collection, and the immortalized canine stem cells, and exosome-rich culture media (ERCM), which is culture media of the stem cells, exhibit excellent effects in suppressing allergy-induced systemic shock responses, alleviating itching caused by atopic dermatitis, suppressing an increase in histamine, alleviating clinical symptoms of rheumatoid arthritis, and the like, and thus may be advantageously used in the treatment of various inflammatory diseases including the aforementioned diseases.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses

Abrégé

The present invention relates to immortalized feline stem cells or use thereof and, in particular, to immortalized feline stem cells and use thereof, the stem cells being obtained by transducing a lentiviral vector comprising the E6 and E7 genes of papillomavirus into feline stem cells and differentiating the stem cells. Particularly, according to the immortalized feline stem cells of the present invention, by transducing the E6 and E8 genes of human papillomavirus into feline stem cells, feline stem cells having the same characteristics and efficacy can be obtained without repeated stem cell harvesting. In addition, the immortalized feline stem cells and an exosome-rich culture medium (ERCM), which is a culture medium of the stem cells, exhibit excellent effects such as the suppression of systemic shock response caused by allergies, the alleviation of itching caused by atopic dermatitis and suppression of an increase in histamines, and the improvement in clinical symptoms due to rheumatoid arthritis, and thus can be effectively used in the treatment of various inflammatory diseases including these diseases.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 15/86 - Vecteurs viraux
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses

Abrégé

The present invention relates to a channel-specific convolution-based convolutional neural network structure for high-speed object recognition using 3D LiDAR, the structure comprising: an in-channel convolution network for extracting a feature in each channel of LiDAR data; an out-channel convolution network for extracting a feature between each channel by using an output of each channel of the in-channel convolution network, and generating a feature map indicating the extracted feature between each channel; and a detection network for scanning the position and the class of an object by using the feature map generated by the out-channel convolution network. The present invention has the advantages in that there is no data loss because, in a process of high-speed object recognition using 3D LiDAR, raw data entering from LiDAR is directly used.

Classes IPC  ?

• G06N 3/04 - Architecture, p. ex. topologie d'interconnexion
• G06N 3/08 - Méthodes d'apprentissage
• G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie

Abrégé

The present invention relates to: a novel 6-methoxy-2-phenethyl isoindoline-1-one derivative compound having an ability to promote nerve growth factor increase, an ability to promote nerve cell growth, and antineuritic activity; and a composition for preventing, improving and treating neurological disorders, comprising same.

Classes IPC  ?

• C07D 209/46 - Iso-indolesIso-indoles hydrogénés avec un atome d'oxygène en position 1
• A61K 31/4035 - Isoindoles, p. ex. phtalimide
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A23K 20/132 - Composés hétérocycliques ne contenant qu’un azote comme hétéroatome

Abrégé

The present invention relates to: a novel 4-methoxy-2-phenethyl isoindoline-1-one derivative compound having the ability to promote nerve growth factor increase, the ability to promote nerve cell growth, and antineuritic activity; and a composition for preventing, alleviating and treating neurological disorders, comprising same.

Classes IPC  ?

• C07D 209/46 - Iso-indolesIso-indoles hydrogénés avec un atome d'oxygène en position 1
• A61K 31/4035 - Isoindoles, p. ex. phtalimide
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A23K 20/132 - Composés hétérocycliques ne contenant qu’un azote comme hétéroatome

Abrégé

The present invention relates to an inhalable formulation comprising nafamostat, camostat or salts thereof. The inhalable formulation can be inhaled through the nose and thus is excellent for preventing or treating a primary nasal infection by a virus, is in a simple form which can easily be self-administered by a patient and can be applied to a patient with an advanced disease via a respirator. Therefore, the present invention can be utilized in technology for preventing or treating coronavirus- or influenza virus-related diseases. Also, the inhalable formulation delivers a drug by means of inhalation unlike an existing oral or injection administration method, and further comprises a substrate which works competitively on esterase and salts which delay elution, and thus inhibits in vivo degradation of nafamostat or camostat to maintain a good residue amount in the applied parts.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/02 - Composés inorganiques
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 31/24 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

An insulation monitoring device, according to various embodiment of the present application, comprising an impedance formed between a power line and a ground of a system comprises, a signal generation circuit for applying a triangular wave signal to the power line through a signal measurement circuit, the signal measurement circuit for measuring a voltage difference across the detection resistor of the signal measurement circuit or a current flowing through the detection resistor when the triangular wave signal is applied to the impedance, a control circuit for obtaining an impedance value of the impedance based on at least one of the voltage difference and the current, and monitoring the impedance value.

Classes IPC  ?

• G01R 31/14 - Circuits à cet effet
• G01R 27/08 - Mesure de la résistance par mesure à la fois de la tension et de l'intensité
• G01R 27/20 - Mesure d'une résistance de terreMesure de la résistance de contact de connexions au sol, p. ex. de plaques
• G01R 27/02 - Mesure de résistances, de réactances, d'impédances réelles ou complexes, ou autres caractéristiques bipolaires qui en dérivent, p. ex. constante de temps
• G01R 27/26 - Mesure de l'inductance ou de la capacitanceMesure du facteur de qualité, p. ex. en utilisant la méthode par résonanceMesure de facteur de pertesMesure des constantes diélectriques
• G01R 19/252 - Dispositions pour procéder aux mesures de courant ou de tension ou pour en indiquer l'existence ou le signe utilisant une méthode de mesure numérique utilisant des convertisseurs analogiques/numériques du type à conversion de la tension ou du courant en fréquence et mesure de cette fréquence
• G01R 31/52 - Test pour déceler la présence de courts-circuits, de fuites de courant ou de défauts à la terre
• G01R 13/02 - Dispositions pour la présentation de variables électriques ou de formes d'ondes pour la présentation sous forme numérique des variables électriques mesurées
• G01R 19/00 - Dispositions pour procéder aux mesures de courant ou de tension ou pour en indiquer l'existence ou le signe
• G01R 29/26 - Mesure du coefficient de bruitMesure de rapport signal-bruit

Abrégé

The present invention relates to a broadband circularly polarized antenna comprising: a square-shaped printed circuit board; a patch which is located on the printed circuit board, which has a square shape in which an opposing vertex part is cut into a triangular shape, and which has a feeding hole; and a meta-surface array which has a grating structure and which is formed in proximity to the patch on the printed circuit board. According to the present invention, a presented planar antenna having a single layer for corresponding to a 5G millimeter wave provides a meta-surface advantage and has high gain and broadband characteristics.

Classes IPC  ?

• H01Q 21/24 - Combinaisons d'unités d'antennes polarisées dans des directions différentes pour émettre ou recevoir des ondes polarisées circulairement ou elliptiquement ou des ondes polarisées linéairement dans n'importe quelle direction
• H01Q 9/04 - Antennes résonnantes

Abrégé

An atomic-force microscope of the present invention may comprise: a sample stage for accommodating a sample; a cantilever to be arranged on the sample and including a probe; a laser for irradiating a laser beam to the cantilever; a photo-detector for receiving the laser beam reflected from the cantilever; a first camera for photographing the sample and the cantilever; a second camera for photographing the cantilever and a laser spot irradiated by the laser; and a processor which is electrically connected to the first camera, the second camera, and the photo-detector and processes data obtained from the photo-detector. A method for operating the atomic-force microscope of the present invention may comprise: a step of sensing the positions of the cantilever and the sample through the first camera; a step of adjusting the position of the sample; a step of sensing the positions of the laser and the cantilever through the second camera; a step of aligning the laser; a step of sensing the position of the laser beam through the photo-detector; and a step of aligning the position of the photo-detector.

Classes IPC  ?

• G01Q 60/00 - Types particuliers de microscopie à sonde à balayage SPM [Scanning-Probe Microscopy] ou appareils à cet effetComposants essentiels de ceux-ci
• G01Q 10/04 - Balayage ou positionnement fin
• G01Q 20/02 - Contrôle du mouvement ou de la position de la sonde par des moyens optiques
• G06T 7/20 - Analyse du mouvement

Abrégé

A method for manufacturing an electrode for alkaline water electrolysis, of the present invention, can comprise the steps of: dissolving a metal salt in a solvent and synthesizing same so as to prepare a wet powder; perform oxidative heat treatment on the wet powder; and perform reductive heat treatment on the wet powder on which oxidative heat treatment has been performed.

Classes IPC  ?

• C25B 11/042 - Électrodes à base d’un seul matériau
• C25B 11/031 - Électrodes poreuses
• C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
• C25B 11/073 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
• C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques

Abrégé

A light source for plant cultivation includes a first light source emitting a first type of light for photosynthesis of a plant and a second light source emitting a second type of light for adjustment of phytochemicals in the plant. The first type of light has at least one peak in the visible spectrum, and the second type of light has a peak in a different wavelength band from the first light source. The second type of light has a peak in the wavelength band of about 360 nm to about 420 nm.

Classes IPC  ?

• A01G 7/04 - Traitement électrique ou magnétique des végétaux pour favoriser leur croissance
• H10H 20/824 - Matériaux des régions électroluminescentes comprenant uniquement des matériaux du groupe III-V, p. ex. GaP
• A01G 22/15 - Légumes-feuilles, p. ex. laitue ou épinards

Abrégé

LactobacillusLactobacillus sp. bacteria-derived extracellular vesicles as an active ingredient, and a method for regulating a stem cell function using same. The Lactobacillus sp. bacteria-derived extracellular vesicles, according the present invention, have the effect of greatly improving the proliferation of stem cells, and the extracellular vesicles are naturally secreted from a Lactobacillus sp. strain symbiotic in human tonsillar tissue and are human-friendly and natural substances, and thus can be used in various research fields by promoting the proliferation of aged stem cells with minimal toxicity and side effects.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12R 1/225 - Lactobacillus

Abrégé

The present invention comprises: a stage on which a sample is placed; a vibration unit configured to generate vibration in the stage; a plurality of probe units having a quartz vibrator and a contact member affixed to the quartz vibrator and provided so as to be able to contact the sample, and each differing in the type of contact member, wherein the plurality of probe units are configured so as to selectively allow one of the probe units to contact the sample; and a control unit for calculating the properties of the sample on the basis of the vibration of the vibration unit and a vibration transmitted to a quartz member via the sample from the vibration of the vibration unit.

Classes IPC  ?

• G01N 11/16 - Recherche des propriétés d'écoulement des matériaux, p. ex. la viscosité, la plasticitéAnalyse des matériaux en déterminant les propriétés d'écoulement en déplaçant un corps à l'intérieur du matériau en mesurant l'effet d'amortissement sur un corps oscillant
• G01N 29/02 - Analyse de fluides
• G01N 29/22 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet Détails

Abrégé

The present invention relates to a chimeric antigen receptor that targets B-cell maturation antigen (BCMA), and use thereof. Immune cells expressing the chimeric antigen receptor of the present invention can be effectively used in the treatment and prevention of B-cell-related diseases, particularly multiple myeloma or non-Hodgkin's lymphoma.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/73 - CD4
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 15/86 - Vecteurs viraux
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to a method for displaying a three-dimensional image in an integrated imaging microscope system that includes an integrated imaging microscope, comprising the steps of: acquiring an integrated image and a two-dimensional image of a sample through an integrated imaging microscope; reconstructing the integrated image into a light field image composed of a plurality of viewpoint images; generating a parallax image, including parallax information, from the light field image; and generating a three-dimensional model by applying the parallax information about the parallax image to the two-dimensional image. According to the present invention, a high-quality three-dimensional image can be visualized for the integrated image acquired by means of the integrated imaging microscope.

Classes IPC  ?

• G02B 21/36 - Microscopes aménagés pour la photographie ou la projection
• G06T 17/20 - Description filaire, p. ex. polygonalisation ou tessellation
• G06T 3/40 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement
• G06T 7/11 - Découpage basé sur les zones

Abrégé

The present invention relates to a process for preparing an isoindolinone derivative represented by Formula 1, novel intermediates used for the process and a process for preparing the intermediates.

Classes IPC  ?

• C07D 265/14 - Oxazines-1, 3Oxazines-1, 3 hydrogénées condensées avec des carbocycles ou avec des systèmes carbocycliques condensées avec un cycle à six chaînons
• C07D 209/46 - Iso-indolesIso-indoles hydrogénés avec un atome d'oxygène en position 1

Abrégé

The present invention includes: a signal generation unit for applying a pulse signal to a power line; a signal measurement unit for measuring the voltage of an applied pulse signal from the ground, when the pulse signal is applied to the ground through insulation resistance; an average voltage calculation unit for calculating the average voltage of the voltages measured during a period depending on sampling intervals; and a control unit for calculating the sampling intervals on the basis of an initial sampling interval and a preset time multiple, calculating the average voltage during the sampling period according to the calculated sampling intervals, and, according to whether the difference between a calculated first average voltage and a second average voltage measured before the first average voltage is within a first error range, detecting the first average voltage as a normal voltage, or calculating the sampling intervals by applying different time multiples thereto.

Classes IPC  ?

• G01R 31/14 - Circuits à cet effet
• G01R 27/02 - Mesure de résistances, de réactances, d'impédances réelles ou complexes, ou autres caractéristiques bipolaires qui en dérivent, p. ex. constante de temps
• H02J 9/00 - Circuits pour alimentation de puissance de secours ou de réserve, p. ex. pour éclairage de secours
• G01R 19/25 - Dispositions pour procéder aux mesures de courant ou de tension ou pour en indiquer l'existence ou le signe utilisant une méthode de mesure numérique
• G01R 19/165 - Indication de ce qu'un courant ou une tension est, soit supérieur ou inférieur à une valeur prédéterminée, soit à l'intérieur ou à l'extérieur d'une plage de valeurs prédéterminée
• G01R 31/12 - Test de la rigidité diélectrique ou de la tension disruptive

Abrégé

The present invention relates to a pharmaceutical composition for preventing or treating obesity or an allergy, comprising a rose extract as an active ingredient. Specifically, the rose extract inhibits adipogenesis in all adipocytes, and suppresses weight gain, production of abdominal adipose tissue, and fatty liver in a mouse while maintaining the physical strength of the mouse, the mouse having been induced with dietary obesity by a high fat diet, and relieves a systemic shock reaction or skin itching caused by an acute allergic reaction, such that the rose extract can be effectively utilized in treating obesity or allergic diseases.

Classes IPC  ?

• A61K 36/738 - Rosa (rose)
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 37/08 - Agents antiallergiques
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention relates to an RNA aptamer that specifically binds to a PPARγ protein and to a use of the RNA aptamer. Specifically, the RNA aptamer according to the present invention strongly binds specifically to the PPARγ protein to inhibit fat differentiation, inhibits the expression of genes and proteins related to fat differentiation, and has the same effect in animal models fed on a high fat diet and thus can be useful in the treatment of obesity as well as for detecting PPARγ protein and for diagnosing obesity.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Abrégé

The present invention relates to an RNA aptamer that specifically binds to LXRα protein and use of the RNA aptamer. Specifically, the RNA aptamer according to the present invention specifically and strongly binds to LXRα protein, inhibits adipose differentiation, and inhibits the expression of adipose differentiation-associated genes and proteins, and thus can be effectively used for LXRα protein detection and fat diagnosis.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention provides a biomarker for predicting effectiveness for autoimmune disease treatment, a diagnostic kit, and a use for treatment. More particularly, the present invention provides a biomarker for predicting the effectiveness of mesenchymal stem cells (MSC) comprising the chemokine receptor CXCR3 for autoimmune disease treatment; a biomarker comprising the chemokine CXCL10 for predicting the prognosis of autoimmune disease treatment; a diagnostic kit comprising an agent capable of measuring the expression of the biomarker; and a pharmaceutical composition for prevention or treatment of an autoimmune disease, which comprises mesenchymal stem cells having an upregulated expression level of the chemokine receptor CXCR3.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to a chimeric antigen receptor (CAR) specifically binding to CD138, an immune cell expressing same, and a pharmaceutical composition for the treatment or prevention of cancer comprising same as an active ingredient. It was confirmed that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the present invention efficiently exhibits strong cytotoxic ability against CD138-expressing (positive) cancer cells. Accordingly, it is expected that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the present invention can be utilized for the treatment of CD138-expressing (benign) cancer diseases.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a biomarker composition for predicting the therapeutic effect of mesenchymal stem cells on systemic lupus erythematosus.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a biomarker composition for predicting a therapeutic effect of a mesenchymal stem cell on renal fibrosis.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Disclosed herein are a G-protein-coupled receptor (GPCR) kinase-interacting protein (GIT) and a use thereof. More particularly, a pharmaceutical composition for prevention or treatment of senescence or senescence-associated disease and a composition for inhibition of cellular senescence, each comprising GIT or a GIT activating agent as an active ingredient, a method for screening a cellular senescence inhibitor, and a method for inhibition of cellular senescence are provided. In senescent cells induced by down-regulation of bPIX expression, GIT or GIT-CT overexpression was found to reduce the expression of senescence markers and to suppress senescence-induced endocytosis reduction. Having an inhibitory activity against cellular senescence, GIT can be thus used as a novel therapeutic agent for senescence or senescence-associated disease.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention relates to a chimeric cytokine receptor capable of converting immunosuppressive signals to immunostimulatory signals, immune cells expressing same, and a pharmaceutical composition comprising the immune cells as an active ingredient for treatment of cancer. The immune cells expressing the chimeric cytokine receptor of the present invention convert immunosuppressive signals to immunostimulatory signals in a tumor microenvironment where immunosuppressive cytokines exist, thereby effectuating more potent cytotoxicity against cancer. The immune cells expressing the chimeric cytokine receptor of the present invention can be used as a cell therapy product for treatment of cancer.

Classes IPC  ?

• C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a monoclonal antibody binding specifically to YKL-40. A high expression level of YKL-40 is associated with the proliferation and metastasis of cancer and a monoclonal antibody to YKL-40 exhibits an effect of inhibiting proliferation and metastasis of cancer. Thus, the monoclonal antibody of the present invention can be advantageously used for diagnosing, preventing, or treating cancer.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61P 35/00 - Agents anticancéreux
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps